Alexander M. M. Eggermont
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander M. M. Eggermont has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Testori
European Institute of Oncology, Milan, Italy
1 shared publication Antoine Yver
Schering-Plough Research Institute
1 shared publicationChristine Xu
Schering-Plough Research Institute
1 shared publicationDirk Schadendorf
Department of Dermatology, University Hospital Essen, Hufelandstr 55, 45122 Essen, Germany
1 shared publicationJohn M. Kirkwood
Medicine and Dermatology, Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
1 shared publicationMarna G. Bouwhuis
Erasmus University Medical Center, Daniel den Hoed Cancer Center
1 shared publication
Latest Publications
- 1 October 2010
- Published by Elsevier in Annals of Oncology
- Vol. 21 (suppl_7) , vii339-vii344
Advances in systemic treatment of melanoma
After decades of phase III trials failing to demonstrate an impact on survival of various drugs in metastatic melanoma there are finally significant advances in systemic therapies for melanoma emerging. Novel ways to modulate the immune system by monoclonal antibodies as well as various signalling pathway inhibitors are responsible for creating a whole new therapeutic landscape. For the first time it is likely that a number of new drugs with completely different mechanisms of action will be approved in the near future. The imminent candidates are the anti-CTLA-4 antibody ipilimumab, and the highly selective BRAF inhibitor PLX4032. But in each class other molecules are under development with good perspectives. Various new combinations will have to be explored and it is reasonable to expect synergies between the different classes of drugs as well as between novel molecules within the same class of drugs. Here, an overview of current developments and the most important new drugs under consideration is provided.
- 1 October 2010
- Published by Elsevier in Annals of Oncology
- Vol. 21 (suppl_7) , vii339-vii344
Advances in systemic treatment of melanoma
After decades of phase III trials failing to demonstrate an impact on survival of various drugs in metastatic melanoma there are finally significant advances in systemic therapies for melanoma emerging. Novel ways to modulate the immune system by monoclonal antibodies as well as various signalling pathway inhibitors are responsible for creating a whole new therapeutic landscape. For the first time it is likely that a number of new drugs with completely different mechanisms of action will be approved in the near future. The imminent candidates are the anti-CTLA-4 antibody ipilimumab, and the highly selective BRAF inhibitor PLX4032. But in each class other molecules are under development with good perspectives. Various new combinations will have to be explored and it is reasonable to expect synergies between the different classes of drugs as well as between novel molecules within the same class of drugs. Here, an overview of current developments and the most important new drugs under consideration is provided.
- Open Access
- 11 November 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (22) , 6745-6747
Immunostimulation Versus Immunosuppression after Multiple Vaccinations: the Woes of Therapeutic Vaccine Development
Three articles in this issue of Clinical Cancer Research show how multiple vaccinations can lead to immunosuppression. Moreover, two studies in patients show that granulocyte macrophage colony-stimulating factor (GM-CSF) as an adjuvant immunostimulant to different kind of vaccines can lead to adverse outcome in terms of relapse-free and overall survival. Modulation of regulatory T-cell activity may be required to overcome this outcome and may be crucial for the successful development of therapeutic vaccines. (Clin Cancer Res 2009;15(22):6745–7)
- 11 November 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (22) , 6745-6747
Open AccessImmunostimulation Versus Immunosuppression after Multiple Vaccinations: the Woes of Therapeutic Vaccine Development
Three articles in this issue of Clinical Cancer Research show how multiple vaccinations can lead to immunosuppression. Moreover, two studies in patients show that granulocyte macrophage colony-stimulating factor (GM-CSF) as an adjuvant immunostimulant to different kind of vaccines can lead to adverse outcome in terms of relapse-free and overall survival. Modulation of regulatory T-cell activity may be required to overcome this outcome and may be crucial for the successful development of therapeutic vaccines. (Clin Cancer Res 2009;15(22):6745–7)
- 1 August 2009
- Published by Elsevier in European Journal of Cancer
- Vol. 45 (12) , 2087-2090
Therapeutic vaccines in solid tumours: Can they be harmful?
- 1 August 2009
- Published by Elsevier in European Journal of Cancer
- Vol. 45 (12) , 2087-2090
Therapeutic vaccines in solid tumours: Can they be harmful?
- 21 July 2009
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 65 (4) , 671-677
Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
The EORTC 18991 trial assessed the effect of long-term adjuvant pegylated interferon (Peg-IFN) α-2b administered weekly in patients with lymph node-positive melanoma. Serum concentrations were analyzed to determine exposure to Peg-IFN α-2b. After surgery, patients were randomized to receive Peg-IFN α-2b or to observation only. The treatment group received 6 μg/kg/week Peg-IFN α-2b subcutaneously for 8 weeks, followed by a maintenance dose of 3 μg/kg/week for up to 5 years. Blood samples were collected between months 3 and 60. A total of 208 Peg-IFN α-2b concentrations from 48 patients were available. Serum trough concentrations increased in a dose-related manner. Mean dose-normalized serum concentrations and intersubject variability over the 5-year study period in patients with melanoma were similar to those observed in patients with chronic hepatitis. Data suggest that the exposure to Peg-IFN α-2b was sustained during long-term adjuvant treatment with Peg-IFN α-2b in patients with melanoma, consistent with the EORTC 18991 trial’s conclusion of a significant, sustained, and relapse-free survival benefit.
- 21 July 2009
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 65 (4) , 671-677
Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
The EORTC 18991 trial assessed the effect of long-term adjuvant pegylated interferon (Peg-IFN) α-2b administered weekly in patients with lymph node-positive melanoma. Serum concentrations were analyzed to determine exposure to Peg-IFN α-2b. After surgery, patients were randomized to receive Peg-IFN α-2b or to observation only. The treatment group received 6 μg/kg/week Peg-IFN α-2b subcutaneously for 8 weeks, followed by a maintenance dose of 3 μg/kg/week for up to 5 years. Blood samples were collected between months 3 and 60. A total of 208 Peg-IFN α-2b concentrations from 48 patients were available. Serum trough concentrations increased in a dose-related manner. Mean dose-normalized serum concentrations and intersubject variability over the 5-year study period in patients with melanoma were similar to those observed in patients with chronic hepatitis. Data suggest that the exposure to Peg-IFN α-2b was sustained during long-term adjuvant treatment with Peg-IFN α-2b in patients with melanoma, consistent with the EORTC 18991 trial’s conclusion of a significant, sustained, and relapse-free survival benefit.
- 1 June 2009
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 23 (3) , 547-564
Melanoma and Immunotherapy
- 1 June 2009
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 23 (3) , 547-564
Melanoma and Immunotherapy
- 1 May 2009
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 6 (5) , 256-258
Vaccine trials in melanoma—time for reflection
The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.
- 1 May 2009
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 6 (5) , 256-258
Vaccine trials in melanoma—time for reflection
The disappointing results of the large, randomized, controlled trials showing no benefit of vaccines in patients with advanced and metastatic melanoma call for a reassessment of the development of therapeutic vaccines and the importance of better immune monitoring methodology, such as adoptive T-cell therapy with lymphodepletion.
- 1 April 2009
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 22 (2) , 156-165
Highlights from the perspectives in melanoma XII conference
The following meeting highlights are from the Perspectives in Melanoma XII conference, held in Scheveningen/The Hague, the Netherlands, on October 2-4, 2008. Selected reviews are included but further discussions of these and other presentations are posted at http://www.MelanomaCare.org.
- 1 April 2009
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 22 (2) , 156-165
Highlights from the perspectives in melanoma XII conference
The following meeting highlights are from the Perspectives in Melanoma XII conference, held in Scheveningen/The Hague, the Netherlands, on October 2-4, 2008. Selected reviews are included but further discussions of these and other presentations are posted at http://www.MelanomaCare.org.